GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

GRAIL, a member of Bio Nebraska, announced a collaboration with Premier, Inc. to use artificial intelligence technology to alert clinicians of patients with elevated cancer risks and may benefit from early detection with Galleri, GRAIL’s multi-cancer early detection blood test.

Announcement from GRAIL

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test.

Under the partnership, Premier’s PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test. The alert will be evidence-based, integrated in the workflow and is expected to be compatible with existing electronic medical record systems. Indianapolis-based Community Health Network is expected to be the first health system to pilot candidate alerts.

“At GRAIL, we are steadfast in our mission to detect cancer early. We are committed to making Galleri available to healthcare providers and eligible patients as a complement to guideline recommended cancer screenings, because we know that most cancers are diagnosed too late, when outcomes are poor,” said Dr. Joshua Ofman, president and chief medical officer at GRAIL. “The partnership with Premier’s PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology – the identification of eligible patients through healthcare providers’ existing workflows.”